Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,722 shares of the pharmaceutical company’s stock after purchasing an additional 48 shares during the quarter. Avior Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,108,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in VRTX. LSV Asset Management raised its stake in Vertex Pharmaceuticals by 206.3% in the 1st quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 3,200 shares during the last quarter. Synovus Financial Corp raised its stake in Vertex Pharmaceuticals by 9.6% in the 1st quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock worth $1,759,000 after acquiring an additional 590 shares during the last quarter. Cibc World Market Inc. raised its stake in Vertex Pharmaceuticals by 69.4% in the 1st quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock worth $1,728,000 after acquiring an additional 2,713 shares during the last quarter. Sei Investments Co. raised its stake in Vertex Pharmaceuticals by 28.4% in the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock worth $11,756,000 after acquiring an additional 9,761 shares during the last quarter. Finally, Cetera Investment Advisers raised its stake in Vertex Pharmaceuticals by 4.0% in the 1st quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after acquiring an additional 544 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Truist Financial lifted their price objective on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group lowered Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and lifted their price objective for the company from $332.00 to $379.00 in a research note on Wednesday, January 24th. Wells Fargo & Company lifted their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Barclays lifted their price objective on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $424.62.

Insider Buying and Selling

In other news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CAO Kristen Ambrose sold 1,374 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $577,409.76. Following the transaction, the chief accounting officer now directly owns 9,676 shares in the company, valued at approximately $4,066,242.24. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the transaction, the chief operating officer now owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,381 shares of company stock worth $5,203,249. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.3 %

VRTX stock opened at $393.10 on Thursday. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 12-month low of $316.43 and a 12-month high of $448.40. The stock has a market cap of $101.60 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 1.84 and a beta of 0.35. The business’s 50-day moving average is $414.76 and its 200 day moving average is $396.76.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The company had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the firm posted $3.33 EPS. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.08 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.